1921
Volume 83, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

A topical nanofiber nitric oxide (NO) releasing patch (≈3.5 μmol NO/cm/day for 20 days, NOP) was compared with intramuscular meglumine antimoniate (Glucantime, 20 mg/kg/day for 20 days) for the treatment of cutaneous leishmaniasis (CL) caused by () in Santander and Tolima, Colombia. A double-blind, randomized, placebo-controlled, clinical trial was conducted to determine whether the NOP is as effective as Glucantime for the treatment of CL. Patients were randomly assigned to Glucantime and placebo patches or NOP and placebo of Glucantime. The cure rates after a 3-month follow-up were 94.8% for the group that received Glucantime compared with 37.1% in the NOP group. Despite the lower efficacy of the NOP versus Glucantime, a significantly lower frequency of non-serious adverse events and a reduced variation in serum markers were observed in patients treated with NOP. Treatment of CL with NOP resulted in a lower effectiveness compared with Glucantime; however, the low frequency of adverse events and the facility of topic administration justify the development of new generations of NOP systems for the treatment of CL.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2010.09-0287
2010-07-01
2017-09-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/83/1/097.html?itemId=/content/journals/10.4269/ajtmh.2010.09-0287&mimeType=html&fmt=ahah

References

  1. Singh S, Sivakumar R, , 2003. Recent advances in the diagnosis of leishmaniasis. J Postgrad Med 49: 5560.[Crossref]
  2. Desjeux P, , 1996. Leishmaniasis. Public health aspects and control. Clin Dermatol 14: 417423.[Crossref]
  3. Herwaldt BL, , 1999. Leishmaniasis. Lancet 354: 11911199.[Crossref]
  4. Panamerican Health Organization, 2008. Leishmaniasis: 2007 update. Available at: http://www.paho.org/English/AD/DPC/CD/leish-2007.htm. Accessed April 29, 2009.
  5. Bern C, Maguire JH, Alvar J, , 2008. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2: e313.[Crossref]
  6. Roberts LJ, Handman E, Foote SJ, , 2000. Science, medicine, and the future: leishmaniasis. BMJ 321: 801804.[Crossref]
  7. Hepburn NC, , 2003. Cutaneous leishmaniasis: an overview. J Postgrad Med 49: 5054.[Crossref]
  8. Silveira FT, Lainson R, Corbett CE, , 2004. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz 99: 239251.[Crossref]
  9. Hepburn NC, Tidman MJ, Hunter JA, , 1993. Cutaneous leishmaniasis in British troops from Belize. Br J Dermatol 128: 6368.[Crossref]
  10. Hendrickx EP, Agudelo SP, Munoz DL, Puerta JA, Velez Bernal ID, , 1998. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am J Trop Med Hyg 59: 889892.
  11. Soto J, Fuya P, Herrera R, Berman J, , 1998. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 26: 5658.[Crossref]
  12. Berman JD, , 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24: 684703.[Crossref]
  13. Miller MA, McGowan SE, Gantt KR, Champion M, Novick SL, Andersen KA, Bacchi CJ, Yarlett N, Britigan BE, Wilson ME, , 2000. Inducible resistance to oxidant stress in the protozoan Leishmania chagasi . J Biol Chem 275: 3388333889.[Crossref]
  14. Diaz NL, Fernandez M, Figueira E, Ramirez R, Monsalve IB, Tapia FJ, , 2003. Nitric oxide and cellular immunity in experimental cutaneous leishmaniasis. Clin Exp Dermatol 28: 288293.[Crossref]
  15. Diefenbach A, Schindler H, Rollinghoff M, Yokoyama WM, Bogdan C, , 1999. Requirement for type 2 NO synthase for IL-12 signaling in innate immunity. Science 284: 951955.[Crossref]
  16. Gantt KR, Goldman TL, McCormick ML, Miller MA, Jeronimo SM, Nascimento ET, Britigan BE, Wilson ME, , 2001. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi . J Immunol 167: 893901.[Crossref]
  17. Kemp M, , 1997. Regulator and effector functions of T-cell subsets in human Leishmania infections. APMIS 68 (Suppl): 133.
  18. Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S, , 1990. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 144: 47944797.
  19. Qadoumi M, Becker I, Donhauser N, Rollinghoff M, Bogdan C, , 2002. Expression of inducible nitric oxide synthase in skin lesions of patients with American cutaneous leishmaniasis. Infect Immun 70: 46384642.[Crossref]
  20. Davidson RN, Yardley V, Croft SL, Konecny P, Benjamin N, , 2000. A topical nitric oxide-generating therapy for cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 94: 319322.[Crossref]
  21. Lopez-Jaramillo P, Ruano C, Rivera J, Teran E, Salazar-Irigoyen R, Esplugues JV, Moncada S, , 1998. Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet 351: 11761177.[Crossref]
  22. Hansen L, Kataphinan W, Reneker D, Smith D, , 2004. Production of superabsorbent electrospun nanofibers. Polym Mater Sci Eng 90: 508.
  23. Lopez M, Lopez-Jaramillo P, Smith D, , 2006. Topical Nitric Oxide Donor Devices. PCT/US2005/043051.
  24. Smith D, , 2005. Stabilization and Ionic Triggering of Nitric Oxide Release. PCT/US2004/023867.
  25. Kenawy el-R, Bowlin GL, Mansfield K, Layman J, Simpson DG, Sanders EH, Wnek GE, , 2002. Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend. J Control Release 81: 5764.[Crossref]
  26. Kenawy el-R, Layman JM, Watkins JR, Bowlin GL, Matthews JA, Simpson DG, Wnek GE, , 2003. Electrospinning of poly(ethylene-co-vinyl alcohol) fibers. Biomaterials 24: 907913.[Crossref]
  27. Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Olliaro P, , 1995. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 53: 648651.
  28. Robledo S, Puerta J, Muñoz D, Guardo M, Velez I, , 2006. Eficacia y tolerancia de la pentamidina en el tratamiento de la leishmaniasis cutánea producida por Leishmania (V.) panamensis en Colombia. Biomedica (Bogota) 26: 188193.[Crossref]
  29. Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, Berman J, , 1997. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 126: 232236.[Crossref]
  30. Hibbs J, Jr Taintor R, Vavrin Z, , 1987. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 235: 473476.[Crossref]
  31. MacMicking J, Xie QW, Nathan C, , 1997. Nitric oxide and macrophage function. Annu Rev Immunol 15: 323350.[Crossref]
  32. De Groote M, Fang F, , 1995. No inhibitions: antimicrobial properties of nitric oxide. Clin Infect Dis 21 (Suppl 2): S162.[Crossref]
  33. Yim C-Y, Bastian N, Smith J, Hibbs J, Samlowski W, , 1993. Macrophage nitric oxide synthesis delays progression of ultraviolet light-induced murine skin cancers. Cancer Res 53: 5507.
  34. Stuehr D, Nathan C, , 1989. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 169: 15431555.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2010.09-0287
Loading
/content/journals/10.4269/ajtmh.2010.09-0287
Loading

Data & Media loading...

  • Received : 26 May 2009
  • Accepted : 23 Dec 2009

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error